 GUANGZHOU, China, April 13, 2021 GLOBE NEWSWIRE -- Burning Rock Biotech Limited NASDAQ: BNR, the Company or Burning Rock today announced that its liquid biopsy assay has achieved strong performance in the FDA-led Sequencing Quality Control Phase 2 SEQC2 study, the results of which have been published on Nature Biotechnology. 